Table of Contents
PISCATAWAY, N.J. – Camber Pharmaceuticals announced the addition of roflumilast 250 mcg tablets to its current portfolio.
Roflumilast tablets are indicated as a treatment to reduce the risk of COPD exacerbations in patients with severe COPD, associated with chronic bronchitis and a history of exacerbations.
Roflumilast 250 mcg tablets are available in 20 and 28 unit-dose cartons.
Roflumilast tablets are also available in 500 mcg strength in 30 and 90 count bottles.